biogen - Search

Also try:

Open links in new tab

Biogen
https://www.biogen.com
Home | Biogen
Biogen is a leader in developing innovative treatments for neurology, neuropsychiatry, immunology and rare diseases. Learn about its science, purpose, careers and latest news.
Pipeline
With a strong focus on difficult-to-treat diseases, our pipeline is focused on res…
News Releases
Biogen TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FIN…
Contact Us
Alzheimer’s Support Alzheimer’s Support Services 1-833-425-9360. Postpartum …
Multiple Sclerosis (MS)
Multiple sclerosis (MS) is a complex, heterogeneous, chronic disease that re…
Leadership Team
Meet our executive leadership team. Inspired by the science: Mother, daught…
Investor Relations
Founded in 1978, Biogen is a leading biotechnology company that pioneers i…
Biogen - Wikipedia
Biotechnology company
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Arge...
See more on Wikipedia
Careers | Biogen
biogen.com
Company | Biogen
biogen.com
Working at Biogen - Glassdoor
Explore Biogen Conversations for the latest discussions among employees who have p…
Glassdoor
Feedback
Thanks!Tell us more

News about Biogen

bing.com › news
Sage, Biogen
✕
About this result
This title and these news articles are related to your search term(s).
Articles come from a variety of sources across the web.
Titles are algorithmically generated based on content related to your search term(s).
· 2d · on MSN
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it …
Zacks.com on MSN · 1d
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
EconoTimes · 1d
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
See all
Related News
· 22h
Biogen Inc. stock underperforms Tuesday when compared to competitors
PMLiVE · 7h
Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA
· 7h
Biogen (BIIB) Gets a Buy from RBC Capital
BioSpace · 8h
RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More
See all
Explore More News
Sage Therapeutics
United States
Leqembi
Nasdaq
Eisai
See more news
Wikipedia
https://en.wikipedia.org › wiki › Biogen
Biogen - Wikipedia
Biogen is a multinational company that develops therapies for neurological diseases. Founded in 1978, it has acquired several other biotech firms and spun off its hemophilia business.
Biogen
https://www.…
Company | Biogen
Biogen is a global leader in biotechnology that develops innovative medicines for neurology, neuropsychiatry, immunology and rare disease. Learn about its science, products, access, …
Tags:
Biogen Idec
Brookfield Incorporações
Fierce Biotech
https://www.fiercebiotech.com › biotech › biogen-lays...
Biogen shrinks research team, zeros in on external innovation
6 days ago · Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro …
Biogen
https://www.biogen.com › science-and-i…
Our Pipeline - Biogen
Biogen is a biotechnology company that develops medicines for difficult-to-treat diseases. Learn about its pipeline of potential therapies and how to participate in clinical trials.
Tags:
Biogen Idec
Biogen Pipeline Chart Recorder
Biogen Pipeline Products Catalog
Interesting reads - Biogen
Powered by MSN
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's accelerated approval process, and is using treatments from Sarepta Therapeutics (NASDAQ:SRPT) and Biogen (NASDAQ:BIIB) as examples. The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.
Seeking Alpha
Here’s Why ClearBridge Growth Strategy Sold Biogen (BIIB)
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to stock-specific weakness in a handful of holdings and a lack of exposure to several of the top-performing, higher-beta growth companies, the strategy underperformed its benchmark the Russell Mid Cap […]
Insider Monkey
Biogen's Quarterly Earnings Preview: What You Need to Know
Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases. Valued at a market capitalization of $20.6 billion, the company's portfolio includes treatments for conditions such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis. BIIB is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Tuesday, Feb. 11.
Barchart
Sage confirms Biogen’s bid to acquire remaining stake
Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all the outstanding shares of common stock that it currently does not own for $7.22 apiece. The Cambridge, Massachusetts-based biotech added that its board of directors, along with its independent financial and legal advisors, will evaluate Biogen’s (NASDAQ:BIIB) bid and decide on the next steps.
Seeking Alpha
Piper Sandler Downgrades Biogen (BIIB)
Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight to Neutral. Analyst Price Forecast Suggests 62.13% Upside As of December 23, 2024, the average one-year price target for Biogen is $243.18/share. The forecasts range from a low of $165.64 to a high of $359.10. The average price target represents an increase of 62.13% from its latest reported closing price of $149.99 / share....
Fintel
Biogen
https://investors.biogen.com › news-releases › news...
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance …
3 days ago · The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
Tags:
Biogen Idec
Alzheimer's disease
Biogen
https://investors.biogen.com
Investor Relations | Biogen
Jan 13, 2025 · Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities.
People also ask
What does Biogen do?
Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
Home | Biogen
biogen.com
Is Biogen a stock?
Biogen stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million.
Biogen - Wikipedia
en.wikipedia.org
What makes Biogen a good company?
Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases.
Home | Biogen
biogen.com
What is Biogen's approach to investing?
Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
Investor Relations | Biogen
investors.biogen.com
Why did we come to Biogen?
We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives.
Home | Biogen
biogen.com
How did Biogen perform in 2017?
For the fiscal year 2017, Biogen reported earnings of US$2.539 billion, with an annual revenue of US$12.274 billion, an increase of 7.2% over the previous fiscal cycle. Biogen's shares traded at over $289 per share, and its market capitalization was valued at over US$63 billion in November 2018.
Biogen - Wikipedia
en.wikipedia.org
Feedback
Biogen
https://investors.biogen.com › news-releases › news...
Biogen Receives U.S. FDA Breakthrough Therapy Designation for ...
Oct 9, 2024 · Biogen announced that felzartamab, an anti-CD38 monoclonal antibody, received Breakthrough Therapy Designation from the FDA for the treatment of antibody-mediated …
Tags:
Biogen Idec
Kidney transplantation
Reuters
https://www.re…
Sage rejects Biogen's $469 million takeover …
2 days ago · Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve …
Tags:
Reuters
Takeover
Biogen
https://www.bio…
Kidney Disease | Biogen
Through our acquisition of Human Immunology Biosciences (HI-Bio) in July 2024, Biogen officially entered the nephrology space with a portfolio of investigational drugs that target immune …
Tags:
Biogen Idec
Nephropathy
People also search for
Related searches for biogen
Some results have been removed
Pagination
- 1
- 2
- 3
- 4
- Next